Shanmugam Muthusamy 4
4 · ANI PHARMACEUTICALS INC · Filed Jun 20, 2024
Insider Transaction Report
Form 4
Shanmugam Muthusamy
DirectorHEAD OF R&D, COO-NOVITIUM OPS
Transactions
- Sale
Common Stock
2024-06-18$60.76/sh−10,607$644,481→ 714,067 total(indirect: By LLC) - Sale
Common Stock
2024-06-20$59.86/sh−11,447$685,217→ 702,620 total(indirect: By LLC) - Sale
Common Stock
2024-06-17$61.41/sh−7,946$487,964→ 724,674 total(indirect: By LLC)
Holdings
- 5,000(indirect: By LLC)
Common Stock
- 68,652
Common Stock
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
- [F2]The shares were sold in multiple trades at prices ranging from $60.77 to $62.55. The price reported above reflects the weighted average sales price.
- [F3]The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
- [F4]The shares were sold in multiple trades at prices ranging from $60.33 to $61.82. The price reported above reflects the weighted average sales price.
- [F5]The shares were sold in multiple trades at prices ranging from $59.40 to $60.50. The price reported above reflects the weighted average sales price.
- [F6]The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.